CCO Independent Conference Coverage
2007 Interscience Conference on Antimicrobial Agents and Chemotherapy*
September 17-20, 2007 | Chicago, Illinois
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
HIV Highlights From ICAAC
|
Track 1 of 1
|
|
|
|
   |
- Joseph J. Eron, Jr., MD
- Joel E. Gallant, MD, MPH
- Trevor Hawkins, MD
|
|
|
Slideset Module
HIV Highlights
|
|
|
Joseph J. Eron Jr., MD, reviews the most clinically relevant new data from the 2007 Interscience Conference on Antimicrobial Agents and Chemotherapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss investigational regimens for the treatment of antiretroviral-naive HIV-infected patients
- Describe the effect of tropism on HIV disease progression and treatment outcomes
- Recall studies of novel agents, including integrase inhibitors and entry inhibitors, for the management of treatment-experienced patients
|
HIV Highlights
 |
|
Joseph J. Eron Jr., MD, discusses the highlights from the 2007 Interscience Conference on Antimicrobial Agents and Chemotherapy
Format: Microsoft PowerPoint (.ppt) |
File size: 1,009 KB
| Date posted: 10/16/2007
|
Expert Highlights
|
Joel E. Gallant, MD, MPH, discusses how data presented at ICAAC 2007 may impact decision making on when to begin antiretroviral therapy. (5 minutes)
|
 |
Download Audio |
|
Trevor Hawkins, MD, reports on efficacy and safety data presented at ICAAC 2007 on the investigational antiretroviral integrase inhibitors raltegravir and elvitegravir. (8 minutes)
|
|
Download Audio |
|
Joseph J. Eron, Jr., MD, discusses new data presented at ICAAC 2007 from the ARTEMIS study comparing the boosted protease inhibitor darunavir/ritonavir with the fixed-dose protease inhibitor lopinavir/ritonavir. (4 minutes)
|
|
Download Audio |
 |
Eric S. Daar, MD, discusses reports on viral tropism and tropism assays and the various types of viral entry inhibitors that were presented at the 2007 ICAAC conference. (12 minutes)
|
|
Download Audio |
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
MOTIVATE Data Suggest Majority of Cases of Treatment Failure on Maraviroc Associated With Outgrowth of Dual/Mixed-Tropic or X4 Virus From Minority Baseline Populations, With Reversion to R5 HIV After Maraviroc Discontinuation
Follow-up data from MOTIVATE trials suggest that preexisting dual/mixed viruses can emerge with maraviroc treatment, although R5 virus reemerges after withdrawal of maraviroc.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|
|